Dr. Mayer

Stories

Giredestrant–everolimus combination improves progression-free survival in advanced breast cancer

As of October 2026: Presented evERA trial results

Patients with estrogen receptor (ER)-positive advanced breast cancer who progress on a CDK4/6 inhibitor have few options left. The Phase III evERA trial found that giredestrant, a pill that degrades the estrogen receptor, plus everolimus cut the risk of progression or death by 44% overall and 62% in ESR1-mutated tumors.

Updated Oct 2

Notable Quotes

In the ESR1-mutant population, the duration of response doubled from about 7 months with standard of care and everolimus therapy to almost 15 months of disease control with giredestrant.

from Giredestrant–everolimus combination improves progression-free survival in advanced breast cancer · Updated Oct 2

There is an urgent need for new and more effective therapies for metastatic ER-positive breast cancers, particularly for patients whose tumors develop resistance to current endocrine therapies and who have progressed following treatment with CDK 4/6 inhibitors. The results we are publishing today show that a novel combination regimen can substantially improve disease control compared to a standard of care regimen and may provide great benefit to a large number of patients with advanced breast cancer.

from Giredestrant–everolimus combination improves progression-free survival in advanced breast cancer · Updated Oct 2